Ge Long Hui·2025-09-16 10:56Core Viewpoint - Xinhua Pharmaceutical (000756.SZ) has received approval from the National Medical Products Administration for its Ursodeoxycholic Acid Capsules, which will enhance its product offerings in the digestive system medication sector [1] Group 1: Product Approval - The approval pertains to Ursodeoxycholic Acid Capsules, which are indicated for the treatment of cholesterol gallstones, cholestatic liver diseases, and bile reflux gastritis [1] - The product is specifically for X-ray penetrable gallstones and requires normal gallbladder contraction function [1] Group 2: Strategic Implications - The approval is expected to enrich the company's range of digestive system medications, thereby improving its overall competitiveness in the pharmaceutical market [1] - The product is anticipated to be officially approved by September 2025, indicating a future growth opportunity for the company [1]